Standout Papers

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid le... 2009 2026 2014 2020 461
  1. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) (2009)
    Patrick P. Zarrinkar, Ruwanthi N. Gunawardane et al. Blood

Immediate Impact

5 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

Catalytic Asymmetric Construction of Chiral Polysubstituted 3-Azabicyclo[3.1.1]heptanes by Copper-Catalyzed Stereoselective Formal [4π+2σ] Cycloaddition
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
1 intermediate paper

Works of Daniel Brigham being referenced

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors
2015
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
2009 Standout

Author Peers

Author Last Decade Papers Cites
Daniel Brigham 378 172 280 10 703
Angelene M. Cantwell 370 111 286 23 828
CC Uphoff 172 50 233 12 580
Richard Stillion 121 83 203 9 700
Michael Paran 242 69 205 14 628
Afsaneh Keyhani 103 43 217 18 591
Laurie Sower 204 67 335 19 774
Dharma R. Thapa 196 189 161 14 629
Kurt Lackovic 104 45 347 23 818
C. Kempf 188 100 376 11 769
Noboru Tamura 321 220 150 14 810

All Works

Loading papers...

Rankless by CCL
2026